Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 6, 2014-- Lorcaserin Evaluated for Effect on the NASH Clinical Score: A Retrospective Analysis of Three Phase 3 Studies --
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the...
-
Nov 3, 2014-- Trial Met Primary Efficacy Endpoint with Statistical Significance After 12 Weeks of Treatment --
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from the Phase 2 trial investigating lorcaserin HCl, a serotonin 2C receptor agonist, for smoking...
-
Oct 31, 2014-- Results of Investigational Study of Coadministration of Lorcaserin and Phentermine Accepted as Late Breaking Poster --
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data for BELVIQ® (lorcaserin HCl) CIV will be presented during ObesityWeekSM hosted by The Obesity Society and the...
-
Oct 28, 2014-- Trial Met Primary Safety Objective After 12 Weeks of Treatment -- -- Data to be Presented at The Obesity Society 2014 Annual Meeting During ObesityWeekSM --
WOODCLIFF LAKE, NJ and SAN DIEGO, CA, October 28, 2014 – Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results of a pilot study to assess the safety of...
- Oct 20, 2014
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor...
